Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $114,224 - $132,252
-320 Reduced 29.52%
764 $300,000
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $367,378 - $548,514
1,084 New
1,084 $412,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Atom Investors LP Portfolio

Follow Atom Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Atom Investors LP with notifications on news.